XOMA Stock Analysis: Buy, Sell, or Hold?
XOMA - XOMA Royalty Corporation Common Stock
$43.00
0.38 (0.89%)
▲
5d:
+1.9%
30d:
+3.14%
90d:
+29.99%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When XOMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XOMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XOMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: XOMA is currently trading at $43.00, which is considered extended relative to its 30-day fair value range of $41.67 to $42.31. From a valuation perspective, the stock is trading at a discount (Forward PE: -860.0) compared to its historical average (44.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XOMA is in a strong uptrend. The price is approaching resistance at $42.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XOMA is in a strong uptrend. The price is approaching resistance at $42.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$41.67 -
$42.31
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($39.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$41.67 -
$42.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$40.76
Resistance Level
$42.75
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-860.00
Wall Street Target
$39.00
(-9.3%)
Revenue Growth (YoY)
-22.6%
Earnings Growth (YoY)
207.9%
Profit Margin
69.6%
PE vs Historical
-860.0 vs 44.1
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:56 PM ET
Data refreshes hourly during market hours. Next update: 11:56 PM
Data refreshes hourly during market hours. Next update: 11:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XOMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
